Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Preventing Fibrosis and Cirrhosis Progression in CHB
NCT05147090Phase 4Active, not recruiting
- Sponsor
- The University of Hong Kong
- Start
- Jan 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Chronic Hepatitis B (CHB), Liver Fibrosis (LF) and Cirrhosis comparing Empagliflozin group with Placebo group (2 arms). Primary endpoint: Change in liver stiffness measured by Magnetic Resonance Elastography at 156 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
Chronic Hepatitis B (CHB)Liver Fibrosis (LF)Cirrhosis
Beyond the preview
Go deeper on NCT05147090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147090.